GLP1R and type 2 diabetes mellitus: Statin use has been associated with increased risk of T2D by poorly understood mechanisms involving both reduced insulin sensitivity and impaired beta cell insulin secretion (Laakso and Fernandes Silva, 2023), the latter ameliorated by GLP-1R agonist exposure (Buldak et al., 2022).